Finance

Lists
Why is 006280 up 2,43%?
Dive Deeper
006280:KRX
GC Biopharma Corp
130 700,00 KRW
+2,43%
(+3 100,00) 1D
19 ოქტ, 15:30:10 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 006280...
Open
127 500 KRW
High
130 900 KRW
Low
126 600 KRW
Mkt. cap
1,53 ტრლ.
Avg. vol.
20,39 ათ.
Volume
18,16 ათ.
Dividend
1,15%
Quarterly dividend
375 KRW
Ex-dividend date
30 მარ. 2026
52-wk high
183 800 KRW
52-wk low
105 900 KRW
EPS
-4 372 KRW
Shares outstanding
11,69 მლნ.
No. of employees
2 ათ.
Open
127 500 KRW
High
130 900 KRW
Low
126 600 KRW
Mkt. cap
1,53 ტრლ.
Avg. vol.
20,39 ათ.
Volume
18,16 ათ.
Dividend
1,15%
Quarterly dividend
375 KRW
Ex-dividend date
30 მარ. 2026
52-wk high
183 800 KRW
52-wk low
105 900 KRW
EPS
-4 372 KRW
Shares outstanding
11,69 მლნ.
No. of employees
2 ათ.
News stories
From web sources and news partners
Profile
GC Biopharma also known as Green Cross Corporation is a biopharmaceutical company headquartered in Yongin, South Korea. Wikipedia
About GC Biopharma Corp
CEOუნ ჩულ ჰა | Il-sup Huh
Employees2,11 ათ.
Founded5 ოქტ. 1967
Headquarters-
Sector-
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
609,49 მლრ.
497,75 მლრ.
435,53 მლრ.
421,18 მლრ.
Cost of goods sold
463,97 მლრ.
357,85 მლრ.
313,13 მლრ.
312,00 მლრ.
Cost of revenue
463,97 მლრ.
357,85 მლრ.
313,13 მლრ.
312,00 მლრ.
Research and development expenses
33,48 მლრდ.
44,81 მლრდ.
35,32 მლრდ.
38,34 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
77,09 მლრდ.
83,01 მლრდ.
70,35 მლრდ.
65,07 მლრდ.
Operating expense
116,30 მლრ.
135,30 მლრ.
110,67 მლრ.
107,45 მლრ.
Total operating expenses
580,27 მლრ.
493,15 მლრ.
423,80 მლრ.
419,45 მლრ.
Operating income
29,21 მლრდ.
4,60 მლრდ.
11,73 მლრდ.
1,73 მლრდ.
Other non operating income
13,04 მლნ.
636,32 მლნ.
-10,15 მლრდ.
-6,20 მლრდ.
EBT including unusual items
24,89 მლრდ.
-110,07 მლრ.
28,59 მლრდ.
-1,60 მლრდ.
EBT excluding unusual items
21,52 მლრდ.
-4,39 მლრდ.
25,91 მლრდ.
-14,17 მლრდ.
Income tax expense
6,74 მლრდ.
-7,27 მლრდ.
8,45 მლრდ.
-2,65 მლრდ.
Effective tax rate
27,07%
6,61%
29,56%
165,54%
Other operating expenses
296,00 მლნ.
306,00 მლნ.
590,00 მლნ.
308,00 მლნ.
Net income
15,95 მლრდ.
-88,30 მლრდ.
20,47 მლრდ.
1,98 მლრდ.
Net profit margin
2,62%
-17,74%
4,70%
0,47%
Earnings per share
1,40 ათ.
-
1,79 ათ.
174,00
Interest and investment income
605,00 მლნ.
623,00 მლნ.
881,00 მლნ.
418,00 მლნ.
Interest expense
-12,76 მლრდ.
-13,40 მლრდ.
-13,27 მლრდ.
-11,50 მლრდ.
Net interest expenses
-12,15 მლრდ.
-12,77 მლრდ.
-12,39 მლრდ.
-11,08 მლრდ.
Depreciation and amortization charges
1,68 მლრდ.
2,17 მლრდ.
1,63 მლრდ.
1,22 მლრდ.
EBITDA
50,70 მლრდ.
24,79 მლრდ.
34,46 მლრდ.
22,90 მლრდ.
Gain or loss from assets sale
-268,00 მლნ.
1,01 მლრდ.
-35,56 მლრდ.
38,60 მლნ.
AI content may include mistakes. Learn more
Google აპები